13F Holdings
中文EN

GPCR Structure Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1888886 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-39.5%
TTM EPS YoY-6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.5%
ROA-27.1%
ROIC (approx.)-32.3%
Asset turnover—

Leverage & solvency

Liabilities / assets8.4%
Debt / equity0.00x
Current ratio11.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue————
R&D expense$225.25M$108.81M$70.10M$36.19M
SG&A expense$61.55M$49.41M$32.67M$16.37M
Operating income-$176.56M-$158.23M-$102.78M-$52.56M
Pretax income-$140.69M-$122.22M-$89.38M-$51.30M
Income tax$515,000$310,000$236,000$17,000
Net income-$141.20M-$122.53M-$89.62M-$51.32M
EBITDA-$175.23M-$157.24M-$102.48M-$52.28M
EPS (basic)-0.80-0.78-0.81-5.51
EPS (diluted)-0.80-0.78-0.81-5.51
Weighted avg. shares (diluted)177.60M157.92M110.20M9.58M
Balance sheet
Cash & equivalents$799.62M$169.51M$129.79M$26.09M
Short-term investments$646.57M$714.01M$337.53M$64.75M
Current assets$1.57B$891.21M$473.61M$93.09M
PP&E, net$6.65M$3.48M$3.23M$1.03M
Total assets$1.58B$903.33M$482.02M$97.84M
Current liabilities$63.28M$36.02M$24.74M$13.01M
Total liabilities$67.54M$38.49M$29.05M$13.01M
Shareholders' equity$1.52B$864.84M$452.97M-$115.14M
Shares outstanding212.51M171.86M139.22M10.53M
Cash flow statement
Operating cash flow-$222.20M-$116.64M-$79.49M-$46.12M
Capital expenditure$3.61M$1.29M$2.17M$155,000
Free cash flow-$225.81M-$117.93M-$81.66M-$46.27M
Investing cash flow$89.80M-$358.91M-$268.34M-$62.11M
Financing cash flow$762.52M$515.26M$451.53M$29.01M
Depreciation & amortization$1.33M$992,000$295,000$277,000
Stock-based compensation$28.99M$18.79M$8.19M$2.51M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.